Anavex

https://finance.yahoo.com/news/anavex-life-sciences-announces-fda-110000099.html

Anavex is certainly the true antagonist of Neuren who is in full advantage anyway. in five sessions following this news, AVXL has been the subject of strong speculation, going from 2.45 to 2.75 with a peak of 3.1 on the day of the announcement, but today at 2.35 so well below the level of ad. this means that the matrix is always the same on these titles in the sense that as long as they do not enter money and only speculation and management of the title. both companies, however, move themselves Rett and rare diseases with the aim of realizing something about Alzheimer's and Parkinson's. the substantial difference between the two companies is that Anavex is ahead with Alzheimer's and Parkinson's and for complement Rett, while Neuren has focused on Rett to transfer knowledge and income in FX and possible Alzheimer's and Parkinson's with 2591.notwithstanding, both titles are treated in the same way; this confirms that for the substance market it does not matter much what you do and how you do it, but how much money you are able to intercept; in our case the catalyst element for this type of investor can not be an important partnership agreement for NNZ-2591. in the short term only this event could make a major change to the title on the market. for this eventuality to be materialized, I consider the granting of the European patent for 2591 to be fundamental.